Our previous clinical trial demonstrated the safety of transplantation of COVID-19 patients with ACE2– MSCs, which substantially improved clinical outcomes.11 Thus, we conducted a randomized, single-blind, placebo-controlled phase II trial to further evaluate the safety and efficacy of transplantation. The gene discussed is ACE2; the disease is COVID-19.